Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 14INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

NET 2Endocrine 2Thoracic 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × surufatinib × 1 year × Clear all
NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05077384 2025-09-16

Open-label Study of Surufatinib in Japanese Patients

Hutchmed

Phase 1/2 Completed
36 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05509699 2025-08-29

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Hutchmed

Phase 2 Completed
21 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT04579679 2025-07-25

Open-Label Surufatinib in European Patients With NET

Hutchmed

Phase 2 Terminated
78 enrolled 20 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡